Several more or less specific ORAI1 inhibitors exist (68–72), and some are currently undergoing clinical trials, as for asthma (RP3128, phase I completed, NCT02958982) (73), COVID-19 pneumonia (Auxora/CM4620, phase II completed, NCT04661540 and NCT04345614) (67, 74), relapsed or refractory lymphomas (RP4010, phase II ongoing, NCT03119467), and acute pancreatitis (Auxora/CM4620, phase II ongoing or completed, NCT03709342, NCT04681066, and NCT03401190). Here, ORAI1 is linked to lymphoma.